Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients

Status Recruiting

Clinical Trial Summary

Muscle cramps markedly affect the quality of life in cirrhotic patients with no highly effective drug. Methocarbamol is a central muscle relaxant used to treat skeletal muscle spasms. The mechanism of action of methocarbamol is currently unknown, but may involve the inhibition of carbonic anhydrase. Methocarbamol has a high therapeutic index, i.e. a wide range of safe and effective dosages.

Clinical Trial Description

Muscle cramps markedly affect the quality of life in cirrhotic patients with no highly effective drug. Abrams et al compared patients with cirrhosis with those with congestive heart failure and found a significantly higher prevalence of weekly or daily cramps with cirrhosis (22%) vs patients with congestive heart failure (5%). Interestingly, there was no difference in diuretic use or dosing between the 2 groups, supporting that factors other than diuretic-mediated effects explained the differences. Methocarbamol is a central muscle relaxant used to treat skeletal muscle spasms. The mechanism of action of methocarbamol is currently unknown, but may involve the inhibition of carbonic anhydrase. Methocarbamol has a high therapeutic index, i.e. a wide range of safe and effective dosages. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02642874
Study type	Interventional
Source	Tanta University
Contact	Sherief M. Abd-Elsalam, Consultant
Phone	00201095159522
Email	sherif_tropical@yahoo.com
Status	Recruiting
Phase	Phase 3
Start date	April 1, 2017
Completion date	December 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04533932` - Endosonographic Shear Wave Elastography for Liver Stiffness
Not yet recruiting	`NCT06031740` - A Comparison of Flexible Endoscopic Polidocanol Liquid and Foam Sclerotherapy in Cirrhotic Patients With Bleeding From Internal Hemorrhoids	N/A
Not yet recruiting	`NCT06026267` - Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis	N/A
Not yet recruiting	`NCT06076330` - Efficacy of 5% Albumin v/s Plasmalyte in Combination With 20% Albumin for Fluid Resuscitation in Cirrhosis With Sepsis Induced Hypotension	N/A
Enrolling by invitation	`NCT05055713` - A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism	N/A
Recruiting	`NCT04578301` - Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
Not yet recruiting	`NCT05515861` - Evaluation of EUS in Preventing Rebleeding After Endoscopic Cyanoacrylate Injection for Gastric Varices	N/A
Not yet recruiting	`NCT05120557` - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH	N/A
Not yet recruiting	`NCT02710227` - Sleep Timing and Circadian Preferences in A Sample of Egyptian Patients With Hepatic Cirrhosis	N/A
Not yet recruiting	`NCT03623360` - Functional MRI to Determine Severity of Cirrhosis
Completed	`NCT02917408` - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Active, not recruiting	`NCT02551250` - Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis
Recruiting	`NCT02239991` - Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant	N/A
Enrolling by invitation	`NCT02256514` - Open Label Trial of Immunotherapy for Advanced Liver Cancer	Phase 2
Terminated	`NCT02311985` - Comparison of Three Transfusion Strategies for Central Venous Catheterization in Cirrhotics: A Randomized Clinical Trial	N/A
Terminated	`NCT01937130` - Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF	Phase 2
Recruiting	`NCT01618890` - Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding	Phase 3
Recruiting	`NCT01724697` - Safety and Efficacy of Human Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis	Phase 1/Phase 2
Recruiting	`NCT01728688` - Safety and Efficacy of Human Autologous Peripheral Blood Stem Cells for Treatment of HBV-related Liver Cirrhosis	Phase 1/Phase 2
Recruiting	`NCT01728727` - Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis	Phase 1/Phase 2